

1. Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. *Cell* 2007;128:669–681.
2. Young RA. Control of the embryonic stem cell state. *Cell* 2011;144:940–954.
3. Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. *Science* 2013;339:1567–1570.
4. Herman JC, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. *N Engl J Med* 2003;349:2042–2054.
5. Jones PA, Baylin SB. The epigenomics of cancer. *Cell* 2007;128:683–692.
6. Baylin SB, Jones PA. A decade of exploring the cancer epigenome — biological and translational implications. *Nat Rev Cancer* 2011;11:726–734.
7. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. *Nat Rev Genet* 2007;8:286–298.
8. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. *Nat Rev Drug Discov* 2006;5:37–50.
9. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. *Cell* 2012;150:12–27.
10. Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. *N Engl J Med* 2012;367:647–657.
11. Bradner J. New targets for hematologic malignancies. *Clin Adv Hematol Oncol* 2013;11:375–376.
12. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? *Cancer Cell* 2012;22:9–20.
13. Allis C, Jenuwein T, Reinberg D. *Epigenetics*, Vol. 1. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2007.
14. Kouzarides T. Chromatin modifications and their function. *Cell* 2007;128:693–705.
15. Baylin SB, Jones PA. Epigenetic determinants of cancer. In: Allis CD, Jenuwein T, Reinberg D, eds. *Epigenetics*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2006: 457–476.
16. Bird AP. CpG-rich islands and the function of DNA methylation. *Nature* 1986;321:209–213.
17. Morey L, Pascual G, Cozzuto L, et al. Nonoverlapping functions of the Polycomb group Cbx family of proteins in embryonic stem cells. *Cell Stem Cell* 2012;10:47–62.
18. Easwaran H, Johnstone SE, Van Neste L, et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. *Genome Res* 2012;22:837–849.
19. Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. *Nat Genet* 2009;41:178–186.
20. Doi A, Park IH, Wen B, et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. *Nat Genet* 2009;41:1350–1353.
21. Herman JC, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. *Cancer Res* 1995;55:4525–4530.
22. Merlo A, Herman JC, Mao L, et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. *Nat Med* 1995;1:686–692.
23. Herman JC, Civin CI, Issa JP, et al. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. *Cancer Res* 1997;57:837–841.
24. Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. *Nat Genet* 2000;24:132–138.
25. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. *Cancer Res* 2006;66:6361–6369.
26. Azad N, Zahnow CA, Rudin CM, et al. The future of epigenetic therapy in solid tumours—lessons from the past. *Nat Rev Clin Oncol* 2013;10:256–266.
27. Issa JP, Kantarjian HM. Targeting DNA methylation. *Clin Cancer Res* 2009;15:3938–3946.
28. Tsai HC, Li H, Van Neste L, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. *Cancer Cell* 2012;21:430–446.
29. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. *Proc Natl Acad Sci U S A* 2002;99:3740–3745.
30. Futscher BW, Oshiro MM, Wozniak RJ, et al. Role for DNA methylation in the control of cell type specific maspin expression. *Nat Genet* 2002;31:175–179.
31. Feldmann A, Ivanek R, Murr R, et al. Transcription factor occupancy can mediate active turnover of DNA methylation at regulatory regions. *PLoS Genet* 2013;9:e1003994.
32. Aran D, Hellman A. Unmasking risk loci: DNA methylation illuminates the biology of cancer predisposition: analyzing DNA methylation of transcriptional enhancers reveals missed regulatory links between cancer risk loci and genes. *Bioessays* 2014;36:184–190.
33. Ziller MJ, Gu H, Muller F, et al. Charting a dynamic DNA methylation landscape of the human genome. *Nature* 2013;500:477–481.
34. Akhtar-Zaidi B, Cowper-Salari R, Corradin O, et al. Epigenomic enhancer profiling defines a signature of colon cancer. *Science* 2012;336:736–739.
35. Kingston R, Tamkun JW. Transcriptional regulation by trithorax group. In: Allis CD, Jenuwein T, Reinberg D, eds. *Epigenetics*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2006: 231–248.
36. Becker PB, Workman JL. Nucleosome remodeling and epigenetics. *Cold Spring Harb Perspect Biol* 2013;5.
37. Petty E, Pillus L. Balancing chromatin remodeling and histone modifications in transcription. *Trends Genet* 2013;29:621–629.
38. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. *Nat Rev Genet* 2012;13:484–492.
39. Bannister AJ, Kouzarides T. Reversing histone methylation. *Nature* 2005;436:1103–1106.
40. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. *Cell Res* 2011;21:381–395.
41. Di Leva G, Carofalo M, Croce CM. MicroRNAs in cancer. *Annu Rev Pathol* 2014;9:287–314.
42. Han BW, Chen YQ. Potential pathological and functional links between long noncoding RNAs and hematopoiesis. *Sci Signal* 2013;6:re5.
43. Xi JJ. MicroRNAs in Cancer. *Cancer Treat Res* 2013;158:119–137.
44. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. *Nature* 1998;393:386–389.
45. Jones PL, Veenstra CJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. *Nat Genet* 1998;19:187–191.
46. Parry L, Clarke AR. The Roles of the Methyl-CpG Binding Proteins in Cancer. *Genes Cancer* 2011;2:618–630.
47. Lopez-Serra L, Esteller M. Proteins that bind methylated DNA and human cancer: reading the wrong words. *Br J Cancer* 2008;98:1881–1885.
48. Cai Y, Geutjes EJ, de Lint K, et al. The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes. *Oncogene* 2014;33:2157–2168.
49. Bestor TH. Cloning of a mammalian DNA methyltransferase. *Gene* 1998;74:9–12.
50. Jair KW, Bachman KE, Suzuki H, et al. De novo CpG island methylation in human cancer cells. *Cancer Res* 2006;66:682–692.
51. Rius M, Lyko F. Epigenetic cancer therapy: rationales, targets and drugs. *Oncogene* 2012;31:4257–4265.
52. Jenuwein T, Allis CD. Translating the histone code. *Science* 2001;293:1074–1080.
53. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. *Nat Rev Drug Discov* 2006;5:769–784.
54. Vaquero A, Scher M, Erdjument-Bromage H, et al. SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation. *Nature* 2007;450:440–444.
55. Pruitt K, Zinn RL, Ohm JE, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. *PLoS Genet* 2006;2:344–352.
56. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. *Nat Genet* 1999;21:103–107.
57. Sorm F, Piskala A, Cihak A, et al. 5-Azacytidine, a new, highly effective cancerostatic. *Experientia* 1964;20:202–203.
58. Taylor SM, Jones PA. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. *Cell* 1979;17:771–779.
59. Jones PA, Taylor SM. Hemimethylated duplex DNAs prepared from 5-azacytidine-treated cells. *Nucleic Acids Res* 1981;9:2933–2947.
60. Lu SH, Ohshima H, Bartsch H. Recent studies on N-nitroso compounds as possible etiological factors in oesophageal cancer. *IARC Sci Publ* 1984;947–953.
61. Taylor SM, Jones PA. Mechanism of action of eukaryotic DNA methyltransferase. Use of 5-azacytosine-containing DNA. *J Mol Biol* 1982;162:679–692.
62. Schaefer M, Hagemann S, Hanna K, et al. Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. *Cancer Res* 2009;69:8127–8132.
63. Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacytidine and decitabine activities in acute myeloid leukemia cell lines. *PLoS One* 2010;5:e9001.
64. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. *Nat Biotechnol* 2010;28:1069–1078.
65. Ferguson AT, Vertino PM, Spitzner JR, et al. Role of estrogen receptor gene demethylation and DNA methyltransferase. DNA adduct formation in 5-aza-2'-deoxycytidine-induced cytotoxicity in human breast cancer cells. *J Biol Chem* 1997;272:32260–32266.
66. Gabbara S, Bhagwat AS. The mechanism of inhibition of DNA (cytosine-5)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor. *Biochem J* 1995;307:87–92.
67. Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. *Proc Natl Acad Sci U S A* 1984;81:6993–6997.
68. Ghoshal K, Datta J, Majumder S, et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. *Mol Cell Biol* 2005;25:4727–4741.

69. Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. *Nat Genet* 2000;25:269–277.
70. Bachman KE, Rountree MR, Baylin SB. Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. *J Biol Chem* 2001;276:32282–32287.
71. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. *Cell* 1980;20:85–93.
72. Berg T, Guo Y, Abdelkarim M, et al. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. *Leuk Res* 2007;31:497–506.
73. Flatau E, Gonzales FA, Michalowsky LA, et al. DNA methylation in 5-aza-2'-deoxycytidine-resistant variants of C3H 10T1/2 Cl8 cells. *Mol Cell Biol* 1984;4:2098–2102.
74. Chan KK, Giannini DD, Starosik JA, et al. 5-Azacytidine hydrolysis kinetics measured by high-pressure liquid chromatography and <sup>13</sup>C-NMR spectroscopy. *J Pharm Sci* 1979;68:807–812.
75. Gore SD, Weng LJ, Figg WD, et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. *Clin Cancer Res* 2002;8:963–970.
76. Yu L, Liu C, Vandeusen J, et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. *Nat Genet* 2005;37:265–274.
77. Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. *J Clin Oncol* 2007;25:3884–3891.
78. Schrump DS, Fischette MR, Nguyen DM, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. *Clin Cancer Res* 2006;12:5777–5785.
79. Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. *J Clin Oncol* 2011;29:2521–2527.
80. Issa JP, Roboz G, Rizzieri D, et al. Abstract LB-214: Interim results from a randomized Phase 1-2 first-in-human (FIH) study of PK/PD guided escalating doses of SGI-110, a novel subcutaneous (SQ) second generation hypomethylating agent (HMA) in relapsed/refractory MDS and AML. *Cancer Res* 2012;72:LB-214.
81. Mund C, Lyko F. Epigenetic cancer therapy: Proof of concept and remaining challenges. *Bioessays* 2010;32:949–957.
82. Popovic R, Licht JD. Emerging epigenetic targets and therapies in cancer medicine. *Cancer Discov* 2012;2:405–413.
83. Verbrugge I, Johnstone RW, Bots M. Promises and challenges of anticancer drugs that target the epigenome. *Epigenomics* 2011;3:547–565.
84. Robert C, Rassool FV. HDAC inhibitors: roles of DNA damage and repair. *Adv Cancer Res* 2012;116:87–129.
85. Kachhap SK, Rosmus N, Collis SJ, et al. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. *PLoS One* 2010;5:e11208.
86. Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. *Cell* 2010;141:69–80.
87. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. *Cancer Cell* 2010;18:683–695.
88. Novogrodsky A, Dvir A, Ravid A, et al. Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. *Cancer* 1983;51:9–14.
89. Miller AA, Kurschel E, Osieka R, et al. Clinical pharmacology of sodium butyrate in patients with acute leukemia. *Eur J Cancer Clin Oncol* 1987;23:1283–1287.
90. Gore SD, Weng LJ, Zhai S, et al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. *Clin Cancer Res* 2001;7:2330–2339.
91. Gore SD, Weng LJ, Figg WD, et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. *Clin Cancer Res* 2002;8:963–970.
92. DiGiuseppe JA, Weng LJ, Yu KH, et al. Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. *Leukemia* 1999;13:1243–1253.
93. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. *Blood* 2004;104:1266–1269.
94. Pilatino C, Cilloni D, Messa E, et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. *Cancer* 2005;104:101–109.
95. Fizzotti M, Cimino G, Pisegna S, et al. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. *Blood* 1995;85:2685–2690.
96. Xu GL, Bestor TH, Bourc'his D, et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. *Nature* 1999;402:187–191.
97. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). *Blood* 2007;109:31–39.
98. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. *J Clin Oncol* 2007;25:3109–3115.
99. O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. *J Clin Oncol* 2006;24:166–173.
100. Ramalingam SS, Maitland ML, Frankel P, et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. *J Clin Oncol* 2010;28:56–62.
101. Giles F, Fischer T, Cortes J, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. *Clin Cancer Res* 2006;12:4628–4635.
102. Richardson PG, Hungria VTM, Yoon S-S, et al. Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma. *ASCO Meeting Abstracts* 2014;32:8510.
103. Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. *Blood* 2001;98:2865–2868.
104. Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. *J Hematol Oncol* 2014;7:11.
105. Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. *J Clin Oncol* 2012;30:631–636.
106. Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. *Clin Cancer Res* 2006;12:3762–3773.
107. Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. *Blood* 2007;109:2781–2790.
108. Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup Trial E1905. *J Clin Oncol* 2014;32:1242–1248.
109. Witt SE, Jotte RM, Konduri K, et al. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. *J Clin Oncol* 2012;30:2248–2255.
110. Yardley DA, Ismail-Khan RR, Melichar B, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a non-steroidal aromatase inhibitor. *J Clin Oncol* 2013;31:2128–2135.
111. Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. *Blood* 2005;105:959–967.
112. Charache S, Dover G, Smith K, et al. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex. *Proc Natl Acad Sci U S A* 1983;80:4842–4846.
113. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. *Leukemia* 1993;7:21–29.
114. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. *J Clin Oncol* 2006;24:3895–3903.
115. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. *J Clin Oncol* 2002;20:2429–2440.
116. Fenaux P, Mufti CJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol* 2009;10:223–232.
117. Fenaux P, Mufti CJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. *J Clin Oncol* 2010;28:562–569.
118. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. *J Clin Oncol* 2000;18:956–962.
119. Wijermans PW, Krulder JW, Huijgens PC, et al. Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. *Leukemia* 1997;11:1–5.
120. Kantarjian HM, O'Brien S, Cortes J, et al. Results of decitabine (5-aza-2'-deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. *Cancer* 2003;98:522–528.
121. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. *Blood* 2007;109:52–57.

122. Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. *J Clin Oncol* 2009;27:3842–3848.
123. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. *Cancer* 2006;106:1794–1803.
124. WijerMans P, Suci S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC Leukemia and German MDS Study Groups. *ASH Annual Meeting Abstracts* 2008;112:226.
125. Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. *Leukemia* 2009;23:1019–1028.
126. Lübbert M, Suci S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. *J Clin Oncol* 2011;29:1987–1996.
127. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. *J Clin Oncol* 2012;30:2670–2677.
128. Sudan N, Rosetti JM, Shaddock RK, et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. *Cancer* 2006;107:1839–1843.
129. Kantarjian HM, O'Brien SM, Keating M, et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. *Leukemia* 1997;11:1617–1620.
130. Ruter B, Wijermans P, Claus R, et al. Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7. *Blood* 2007;110:1080–1082.
131. Raj K, John A, Ho A, et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. *Leukemia* 2007;21:1937–1944.
132. Ravandi F, Issa JP, Garcia-Manero G, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. *Cancer* 2009;115:5746–5751.
133. Yang AS, Doshi KD, Choi SW, et al. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. *Cancer Res* 2006;66:5495–5503.
134. Yang AS, Estecio MR, Doshi K, et al. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. *Nucleic Acids Res* 2004;32:e38.
135. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. *Blood* 2002;100:2957–2964.
136. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. *Nature* 2003;421:499–506.
137. Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. *Leuk Lymphoma* 2008;49:690–695.
138. Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. *J Clin Oncol* 2010;28:605–613.
139. Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. *Blood* 2009;114:3448–3458.
140. Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. *Blood* 2009;114:2764–2773.
141. Schuebel KE, Chen W, Cope L, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. *PLoS Genet* 2007;3:1709–1723.
142. Maslak P, Chanel S, Camacho LH, et al. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. *Leukemia* 2006;20:212–217.
143. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase I/II study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. *Blood* 2006;108:3271–3279.
144. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. *Blood* 2007;110:2302–2308.
145. Voso MT, Santini V, Finelli C, et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. *Clin Cancer Res* 2009;15:5002–5007.
146. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. *Carcinogenesis* 2010;31:27–36.
147. Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. *Cancer* 2011;117:2697–2702.
148. Craddock C, Quek L, Goardon N, et al. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. *Leukemia* 2013;27:1028–1036.
149. Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. *Cancer Discov* 2011;1: 598–607.
150. Wrangle J, Wang W, Koch A, et al. Alterations of immune response of Non-Small Cell Lung Cancer with Azacitidine. *Oncotarget* 2013;4:2067–2079.
151. Shakya R, Gonda TA, Quante M, et al. Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma. *Cancer Res* 2013;73: 885–896.
152. Humeniuk R, Menon LG, Mishra PJ, et al. Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. *Mol Cancer Ther* 2009;8:1037–1044.
153. Meng F, Sun G, Zhong M, et al. Anticancer efficacy of the combination of low-dose cisplatin and trichostatin A or 5-aza-2'-deoxycytidine in ovarian cancer cells. Paper presented at: 2012 ASCO Annual Meeting; 2012; Chicago, IL.
154. Matei D, Fang F, Shen C, et al. Epigenetic resensitization to platinum in ovarian cancer. *Cancer Res* 2012;72:2197–2205.
155. Fu S, Hu W, Iyer R, et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. *Cancer* 2011;117:1661–1669.
156. Chung CW, Coste H, White JH, et al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains. *J Med Chem* 2011;54:3827–3838.
157. Bernt KM, Zhu N, Sinha AU, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. *Cancer Cell* 2011;20:66–78.
158. Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. *Cancer Cell* 2011;20:53–65.
159. Spannhoff A, Hauser AT, Heinke R, et al. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. *ChemMedChem* 2009;4:1568–1582.
160. Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. *Cell* 2005;121:167–178.